Clinical Trials Logo

Clinical Trial Summary

This is a non-randomized, non-blinded, pilot study administering hyperthermic intraperitoneal chemotherapy with Mitomycin-C in 10 men and women with muscle-invasive urothelial carcinoma of the bladder undergoing radical cystectomy with pelvic lymph node dissection who have risk factors for tumor recurrence.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03514888
Study type Interventional
Source Weill Medical College of Cornell University
Contact
Status Completed
Phase N/A
Start date April 19, 2018
Completion date May 23, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Completed NCT02924480 - Intravenous Lidocaine for Cystectomy Procedures N/A
Recruiting NCT05783271 - Multiparametric Magnetic Resonance Imaging Performance in Detection of Occult Muscle Invasion in Urinary Bladder Cancer
Active, not recruiting NCT03702179 - Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach Phase 2
Completed NCT03862105 - Testing the Utilization of a Mobile Health App for Patients Undergoing Cystectomy Surgery for Bladder Cancer N/A
Recruiting NCT02560636 - Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer Phase 1
Active, not recruiting NCT02030574 - Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin Phase 2
Recruiting NCT03844256 - A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study Phase 1/Phase 2
Active, not recruiting NCT04134000 - Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) Phase 1
Terminated NCT03498196 - A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04523038 - Nordic Cystectomy Study II - Albumin
Recruiting NCT04523025 - Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)
Withdrawn NCT01922232 - MRI and Bladder Cancer Chemotherapy N/A